TM Owner Sanofi (sanofi-aventis U.S. LLC; EU: Sanofi Winthrop Industrie)
Ziv-Aflibercept IV 100mg/4mL Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Ziv-Aflibercept IV 100 mg/4 mL is not a brand name; the approved product is Zaltrap (ziv-aflibercept) 25 mg/mL concentrate for intravenous infusion, and this information comes from the Zaltrap label.
- Ziv-aflibercept is a VEGF-blocking biologic that binds vascular endothelial growth factor and placental growth factor and so limits tumour blood vessel growth.
- It is approved, in combination with FOLFIRI chemotherapy (irinotecan, 5-fluorouracil and folinic acid), for adults with metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing regimen.
- The US dose is 4 mg/kg by intravenous infusion over 1 hour every 2 weeks; it is given only by a healthcare professional in a clinic or hospital.
- It is supplied as 100 mg/4 mL and 200 mg/8 mL vials, and the EU authorisation is held by Sanofi Winthrop Industrie.
Side Effects
- Very common side effects (20% of patients or more) in the US label include low white blood cells (leukopenia 78%), diarrhea (69%), neutropenia (67%), protein in the urine (62%), raised liver enzymes, mouth sores (stomatitis 50%), fatigue (48%), low platelets (48%) and high blood pressure (41%).
- Others include weight loss, decreased appetite, nosebleeds, abdominal pain, hoarse voice and headache.
- Serious reactions include severe or fatal bleeding (any bleeding 38%), gastrointestinal perforation, fistula formation, impaired wound healing, arterial blood clots, severe high blood pressure, kidney protein loss, severe neutropenia, severe diarrhea with dehydration, and reversible posterior leukoencephalopathy syndrome (headache, confusion, seizures, vision changes).
- The current US label has no boxed warning.
- Report bleeding, severe abdominal pain, chest pain, severe headache or fever straight away.
Precautions & Warnings
- Zaltrap is for intravenous infusion only and must never be given as an intravenous push or bolus.
- It is given through a 0.2-micron polyethersulfone filter after dilution.
- Blood counts are checked before each cycle, and treatment is delayed if neutrophils fall below 1.5 x 10 to the 9th per litre.
- Blood pressure is checked every 2 weeks and urine protein is monitored.
- Treatment is suspended at least 4 weeks before elective surgery and restarted no sooner than 4 weeks after, once the wound has healed.
- It is stopped permanently for severe bleeding, gastrointestinal perforation, fistula, arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, thrombotic microangiopathy or reversible posterior leukoencephalopathy.
- It can cause fetal harm: use effective contraception during treatment and for 3 months after the last dose, and avoid breastfeeding.
- The label lists no contraindications.
- Vials are stored at 2 C to 8 C in the original carton.
Avoid Interactions
- The US label reports no clinically important interactions between ziv-aflibercept and irinotecan, 5-fluorouracil or leucovorin, the FOLFIRI medicines it is given with; the side effects of the chemotherapy add to those of Zaltrap, so blood counts, diarrhea and hydration are watched closely.
- No medicines that reduce its effect were identified in the label.
- Pharmacy handling matters: dilute only in 0.9% sodium chloride or 5% dextrose to 0.6 to 8 mg/mL, use PVC bags containing DEHP or polyolefin bags, and never use PVDF or nylon filters.
- Tell your care team about all medicines and supplements you take, especially blood thinners and blood pressure medicines, and about any planned surgery or dental work.
References
Frequently Asked Questions
Zaltrap (ziv-aflibercept) is used with FOLFIRI chemotherapy to treat adults with metastatic colorectal cancer that has resisted or progressed after an oxaliplatin-based regimen. It blocks VEGF, which limits tumour blood vessel growth. It is given only by healthcare professionals in a clinic or hospital, by infusion into a vein.
Zaltrap (ziv-aflibercept) is given in a clinic or hospital as an intravenous infusion of 4 mg/kg over 1 hour, once every 2 weeks, together with FOLFIRI. It is never given as an intravenous push or bolus. Your care team prepares it and runs the infusion.
Common Zaltrap side effects include low white blood cells, diarrhea, protein in the urine, mouth sores, tiredness and high blood pressure. Serious effects are severe bleeding, bowel perforation, fistulas, poor wound healing and blood clots. Tell your team at once about bleeding, severe stomach pain, chest pain or severe headache.
Avoid elective surgery for at least 4 weeks before and after Zaltrap (ziv-aflibercept) because it impairs wound healing. Avoid pregnancy and breastfeeding during treatment; use effective contraception for 3 months after the last dose. No clinically important interactions with the FOLFIRI medicines were found.
During Zaltrap (ziv-aflibercept) treatment you have a blood count before every cycle, blood pressure checks every 2 weeks, and urine tests for protein. Treatment is delayed if neutrophils are below 1.5 x 10 to the 9th per litre, and paused for uncontrolled high blood pressure or heavy proteinuria.
Zaltrap (ziv-aflibercept) is stopped permanently after severe bleeding, bowel perforation, fistula formation, arterial blood clots, hypertensive crisis, nephrotic syndrome, thrombotic microangiopathy or reversible posterior leukoencephalopathy syndrome. Your care team decides this and monitors you closely. Report any sudden severe symptom, such as heavy bleeding or severe stomach pain, straight away.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.